Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Harvard Business School
Johnson and Johnson
Colorcon
Mallinckrodt

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BENICAR HCT

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Benicar Hct

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00122447 Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance Completed Daiichi Sankyo Inc. N/A 2005-05-01 The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.
NCT00122447 Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance Completed National Center for Research Resources (NCRR) N/A 2005-05-01 The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.
NCT00122447 Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) N/A 2005-05-01 The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.
NCT00122447 Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance Completed Emory University N/A 2005-05-01 The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.
NCT00185068 An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension Completed Daiichi Sankyo Inc. Phase 4 2004-03-01 Effect of increasing doses of olmesartan medoxomil and olmesartan medoxomil/hydrochlorothiazide on blood pressure in patients with hypertension
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Benicar Hct

Condition Name

Condition Name for Benicar Hct
Intervention Trials
Healthy 4
Hypertension 2
Healthy Subjects 2
Essential Hypertension 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Benicar Hct
Intervention Trials
Hypertension 3
Prediabetic State 1
Glucose Intolerance 1
Cardiovascular Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Benicar Hct

Trials by Country

Trials by Country for Benicar Hct
Location Trials
United States 63
Mexico 5
Chile 4
Argentina 1
Peru 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Benicar Hct
Location Trials
North Dakota 4
Oklahoma 3
New York 3
Maine 3
Florida 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Benicar Hct

Clinical Trial Phase

Clinical Trial Phase for Benicar Hct
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Benicar Hct
Clinical Trial Phase Trials
Completed 10
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Benicar Hct

Sponsor Name

Sponsor Name for Benicar Hct
Sponsor Trials
Mylan Pharmaceuticals 4
Torrent Pharmaceuticals Limited 2
Daiichi Sankyo Inc. 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Benicar Hct
Sponsor Trials
Industry 10
NIH 2
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Baxter
Boehringer Ingelheim
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.